Fenglin B. Li

Ningbo, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Oleandrin Suppresses the PI3K/AKT Pathway to Inhibit Growth and Induce Apoptosis in T-cell Acute Lymphoblastic Leukemia Cells and Xenograft Mice.

Oleandrin Suppresses the PI3K/AKT Pathway to Inhibit Growth and Induce Apoptosis in T-cell Acute Lymphoblastic Leukemia Cells and Xenograft Mice.

Journal: Planta medica
Published: March 05, 2026

Exposure Sequence of Photoaging and Natural Organic Matters Governs the Complex Release Dynamics of Additives from Tire Tread Particles.

Exposure Sequence of Photoaging and Natural Organic Matters Governs the Complex Release Dynamics of Additives from Tire Tread Particles.

Journal: Environmental science & technology
Published: February 05, 2026

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis.

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis.

Journal: Anti-cancer drugs
Published: May 06, 2025

HERV-K TM Subunit Elicits CD8+ T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC.

HERV-K TM Subunit Elicits CD8+ T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 23, 2024

Trends and projections of the global and regional burden of multiple myeloma in adults aged 40 and over, 1990-2044.

Trends and projections of the global and regional burden of multiple myeloma in adults aged 40 and over, 1990-2044.

Journal: Scientific reports
Published: November 21, 2024

Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?

Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?

Journal: Journal of translational medicine
Published: November 05, 2024

High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia.

High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia.

Journal: Biochemical genetics
Published: October 09, 2024

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting.

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting.

Journal: Discover oncology
Published: August 10, 2024

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia.

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia.

Journal: Hematology (Amsterdam, Netherlands)
Published: August 01, 2024

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.

Journal: Journal of translational medicine
Published: July 18, 2024

A new perspective on hematological malignancies: m6A modification in immune microenvironment.

A new perspective on hematological malignancies: m6A modification in immune microenvironment.

Journal: Frontiers in immunology
Published: January 22, 2024

Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.

Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.

Journal: Blood
Published: November 27, 2023
Showing 1-12 of 46

Last Updated: 09/26/2026